Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

New nonnucleoside reverse transcriptase inhibitors.

GMHC treatment issues : the Gay Men's Health Crisis newsletter of experimental AIDS therapies - 1 Feb 1999

Abstract excerpt

Five nonnucleoside reverse transcriptase inhibitors (NNRTIs) that are being developed were presented at the 6th Conference on Retroviruses and Opportunistic Infections. All currently approved NNRTIs have cross-resistance to each other, so drug companies are attempting to formulate new NNRTIs that will be potent against HIV strains resistant to other drugs in the same class. For instance, DuPont has two compounds...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cells, Cultured
Share to Drug Industry
Share to Drug Resistance, Microbial

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drugs, Investigational

Share to HIV Infections

Share to In Vitro Techniques

Share to Reverse Transcriptase Inhibitors

Source

Identifiers

PMID: 11366114

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

New nonnucleoside reverse transcriptase inhibitors.PMID 11366114Read ↗

New non-nucleoside reverse transcriptase inhibitors (NNRTIs) in development for the treatment of HIV infectionsSemantic proximity Read ↗

New nucleoside reverse transcriptase inhibitors for the treatment of HIV infectionsSemantic proximity Read ↗

Clinical Utility of Current NNRTIs and Perspectives of New Agents in This Class under DevelopmentSemantic proximity Read ↗

Druggability modification strategies of the diarylpyrimidine‐type non‐nucleoside reverse transcriptase inhibitorsSemantic proximity Read ↗

The Emerging Profile of Cross-Resistance among the Nonnucleoside HIV-1 Reverse Transcriptase InhibitorsSemantic proximity Read ↗

Next-generation HIV-1 non-nucleoside reverse transcriptase inhibitors.Semantic proximity Read ↗

Emivirine: an NRTI that functions as an NNRTI.Semantic proximity Read ↗

Cross-resistance analysis and molecular modeling of nonnucleoside reverse transcriptase inhibitors targeting drug-resistance mutations in the reverse transcriptase of human immunodeficiency virus.Semantic proximity Read ↗

Anti-human immunodeficiency virus type 1 activity of the nonnucleoside reverse transcriptase inhibitor GW678248 in combination with other antiretrovirals against clinical isolate viruses and in vitro selection for resistance.Semantic proximity Read ↗

SJ-3366, a unique and highly potent nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 (HIV-1) that also inhibits HIV-2.Semantic proximity Read ↗

A new nucleoside analogue.Semantic proximity Read ↗

Discovery of non-nucleoside inhibitors of HIV-1 reverse transcriptase competing with the nucleotide substrate.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.